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ABSTRACT
The goal of this current research was to explore the role of a putative membrane AR in
modulating the viability of various models of glioma/astrocytoma, relative to normal (nontumor) astrocytes. Our lab previously found that ligand binding to a putative membrane AR
increases cell vulnerability to the metabolic/oxidative stressor, Iodoacetic acid (IAA), and
suggested that the same may be true for the chemotherapeutic, temozolomide (TMZ). Given that
the cellular damage elicited by these two compounds is through two distinct mechanisms, we
proposed to more carefully characterize the “damage-promoting” consequence of ligand
(Testosterone-BSA, T-BSA) binding to the membrane AR and determine if: 1) the consequence
of T-BSA is mechanism (of cytotoxicity)-specific, and 2) if T-BSA exerts similar effects in
primary (“healthy” or “normal”) astrocytes relative to glial tumor cells (astrocytomas). Our data
revealed that the effectiveness of T-BSA (and thus, engaging a putative membrane AR) is
context specific, with the most robust effect (of sensitizing the cells to either IAA or TMZ) noted
in C6 glioma cells. Moreover, our data suggest that T-BSA may have minimal impact on
enhancing the effects of TMZ in “normal” astrocytes, suggesting the possibility that exploiting
the membrane AR could enhance the demise of the tumor cells while leaving “normal” (and
perhaps, healthy) astrocytes unscathed. While our data certainly support the need for additional
studies, with complementary tools to interrogate the role of the putative membrane AR, the data
also lay the foundation for the development of novel therapeutics targeting the membrane
androgen receptor, the impact of which would be to facilitate the development of new

viii

ix
therapeutics for such devastating glial tumors as glioblastoma multiforme, for which the
prognosis is very poor.

CHAPTER ONE
INTRODUCTION
In mammalian systems, androgens are classified as one of the six families of steroid
hormones [11]. Testosterone, a principal androgen, is highly conserved among vertebrates as it
plays an important role in evolution and development [12]. While testosterone is typically
associated with its role in reproduction, androgens also affect a wide variety of tissues including
skin, bone, muscle, and brain [1, 28]. Within these tissues, testosterone and its metabolite 5αdihydrotestosterone (DHT) exert their effects primarily through binding with the androgen
receptor (AR) [1,2]. The AR belongs to the nuclear hormone receptor super-family and
characteristic of this receptor super-family, binding of androgens initiates a conformational
change that allows the AR to be translocated into the nucleus to interact with DNA as a
transcription factor [1,3,5]. This model of androgen action presumes the steroid is capable of
freely crossing the plasma membrane to enter the cytoplasm where it can bind to and activate the
AR [4,5]. This mechanism of intracellular AR activity is referred to as the "classical" or genomic
model.
In addition to the classical AR, a growing body of evidence suggests that androgens are
capable of eliciting non-genomic actions as well, likely through a receptor alternative to the AR.
Distinct membrane receptors have been identified for other steroid hormones, which suggests a
novel membrane androgen receptor may also exist [4]. The way by which androgens, through
mechanisms that include potentially novel, putative membrane-associated receptors, are thought
to elicit non-genomic actions is through activation of second messenger pathways, including the
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extracellular signal regulated kinase 1/2 (ERK1/2) and PI3K-Akt pathways [13]. The ERK1/2
cascade is an integral signaling pathways that regulates a variety of cellular processes, including
differentiation, proliferation, and survival, as well as apoptosis and stress response [17,18, 33,
35]. The PI3-K/Akt pathway is another integral signaling pathway which mediates several
cellular functions such as angiogenesis, metabolism, growth and proliferation, survival, protein
synthesis, and apoptosis [19, 36, 37].
Although androgens have previously been shown to play a role in neuroprotection,
previous research from our laboratory suggests that ligand binding to a putative membrane
androgen receptor may induce damaging effects in certain cell types [20,21,22]. Joshua Gatson et
al. (2005) found evidence that androgens, particularly DHT, are capable of regulating ERK and
PI3-K/Akt pathways through a novel membrane androgen receptor in rat glioma cells [21]. One
aspect of these experiments aimed to address whether the effect of DHT was being mediated
through the classical AR, or if a membrane AR may be involved [21]. It was shown that when
cells were treated with DHT, there was a robust increase in the expression of both
phosphorylated ERK and phosphorylated Akt; it was also shown that the effect of DHT on ERK
phosphorylation was blocked by the classical AR antagonist flutamide, which may suggest the
classical AR is mediating this change in ERK phosphorylation [21]. Notably, these experiments
also showed that treatment with a membrane impermeable androgen conjugate, DHT-conjugated
to bovine serum albumin (DHT-BSA), led to a substantial suppression of ERK and Akt
phosphorylation. In contrast to treatment with DHT, the effect of DHT-BSA was insensitive to
flutamide, suggesting a novel receptor may be involved [21]. In later work also done by Joshua
Gatson (2007), this research was extended to primary cortical astrocytes to assess the effects of
DHT-BSA on the cell’s sensitivity to a metabolic/oxidative insult [20]. In these experiments, a
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metabolic/oxidative insult was elicited by treatment with Iodoacetic Acid (IAA). IAA acts by
inhibiting glyceraldehyde-3-phosphate dehydrogenase, a key glycolytic enzyme, resulting in a
substantial decrease in cellular ATP and leading to cell death [20,26]. It was shown that
combined treatment with DHT-BSA greatly enhanced the effect of IAA alone on induced cell
death [20]. These experiments also showed that combined treatment with DHT-BSA and IAA
greatly exacerbated the decline in levels of phosphorylated Akt, as well as decreasing overall
expression of Akt [20].
As previously mentioned, the ERK and PI3-K/Akt pathways are tightly regulated and
critical for cell maintenance/viability. Due to their importance, dysfunction of these signaling
cascades can lead to various pathologies including neurodegenerative diseases and cancers [17,
18, 23, 29, 30, 31, 34]. In fact, it has been shown that activating mutations in the ERK cascade
occurs in most cancer types and mutations in this pathway are a major oncogenic factor across all
cancer types [17,18, 32]. Additionally, it has been shown that overexpression of Akt has an antiapoptotic effect in many cell types, which can contribute to cancer pathology and poor prognosis,
in part, due to a resulting increase in the resistance of the cancer to anti-tumor agents [23, 38,
39]. Conversely, inducing inhibition of PI3-K, thus reducing Akt activity, can block cellular
proliferation while inhibition of ERK signaling pathways can restore tumor cells to a nontransformed state [23, 8]. With evidence from our lab suggesting that decreased expression of
phosphorylated ERK and Akt can be elicited by application of the putative membrane-associated
androgen receptor, DHT-BSA, we hypothesized that this mechanism could be exploited in the
treatment of certain cancers.
To further explore the idea that cell vulnerability (specifically of cancer cells) can be
influenced by ligand binding to a putative membrane AR, we extended our research into human
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glioblastoma cells to assess whether treatment with membrane impermeable androgens enhances
cell vulnerability in response to a chemotherapeutic. These studies utilized two human
glioblastoma cell lines, A172 and T98G, to determine how treatment with a membrane
impermeable androgen, testosterone-BSA (T-BSA), might affect cell viability in the presence of
the chemotherapeutic Temozolomide (TMZ) [22].
TMZ is an alkylating drug that acts through methylation of the O6 position of guanine,
resulting in DNA lesions which are considered to be responsible for the cytotoxic effect. The
presence of the DNA repair enzyme, O6-methylguanine DNA methyltransferase (MGMT), can
cause resistance to alkylating agents, such as TMZ, by removing the methyl group from the O6
position of guanine [24, 42]. Our lab was interested in using both A172 and T98G glioblastoma
cell lines due to their difference in responsiveness to TMZ, likely caused by their difference in
expression of MGMT. A172 cells are considered TMZ-sensitive and express low MGMT
activity, whereas T98G cells are considered TMZ-insensitive and express high MGMT activity
[24, 25, 47]. Our lab showed that while treatment with TMZ alone showed a decrease in A172
cell viability, this effect was significantly enhanced with the administration of T-BSA; T98G
cells, which were unresponsive to TMZ treatment alone, also showed a decrease in cell viability
with the administration of T-BSA [22]. Further experiments showed treatment with T-BSA
significantly decreased mRNA levels of MGMT in T98G cells, compared to T98G cells not
treated with T-BSA [22]. Additionally, it was shown that inhibition of Akt resulted in decreased
levels of MGMT protein [22]. Collectively, these results suggest that ligand binding to the
putative membrane AR can influence cell responsiveness to cytotoxic insult, possibly through
changes in MGMT expression mediated by the Akt pathway [22].
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While the classical AR has been implicated in the protective effects of androgens,
binding to the membrane AR, in contrast, appears to favor cell death; this may suggest that the
balance between the classical AR and the membrane AR modulates the effect of androgens on
cell function/viability. Given that binding to the membrane AR was associated with a decrease in
both ERK1/2 and Akt phosphorylation, this suggests as a mechanism by which cell sensitivity to
cytotoxic insult can be manipulated through exploitation of the “death-promoting” membrane
AR. This proposes the idea that the putative membrane AR could potentially serve as a novel
therapeutic target for treatment of glial tumors, specifically glioblastoma, by sensitizing cells to
TMZ.
Gliomas are the most common primary brain tumors in adults, accounting for more than
70% of all primary central nervous system tumors [6]. Glioblastomas, the most frequent and
most malignant subtype of glioma, account for 45.6% of primary malignant brain tumors [6,7].
Defining histopathologic features of glioblastoma include necrosis and microvascular
proliferation and like other cancers, glioblastoma exhibits characteristic malignant phenotypes
such as self-sustained proliferation, evasion of external growth control, and tissue invasion [7, 8,
40, 43]. Despite glioblastomas being highly invasive, capable of invading the surrounding brain
parenchyma, they are typically confined within the central nervous system and do not
metastasize [10].
While the frequency of glioblastoma is low (3 per 100,000) compared to cancers
originating from other organs, glioblastoma is a highly aggressive cancer associated with
significant morbidity and mortality [7,8]. The incidence rate for glioblastoma varies by both sex
and age [16]. Compared to females, glioblastoma is 1.58 times more common in males [16]. The
median age at diagnosis is 65 years and rates are highest in the age group of 75-84 years [16].

6
Glioblastoma often develop rapidly in elderly patients after short clinical history; the average
time of progression from low-grade glioma to glioblastoma is 5.3 years [6, 9]. Patient survival is
inversely associated with age; 5% of patients diagnosed with glioblastoma are alive after 5 years,
but this measure decreases to 2% among patients aged 65 years and older [7].
Although glioblastoma prognosis is invariably fatal, standard treatment options, including
surgical resection, radiation, and chemotherapy, may stabilize or improve quality of life and
cognitive function for a period of time [14,10,15,16]. A glioblastoma diagnosis is initially
achieved by neuroimaging followed by resection or biopsy of tumor tissue to establish a
definitive diagnosis, and determine tumor grade and characteristics [15,7,10]. While maximal
surgical resection aims to relieve mass effect, both resection and biopsy can present risks such as
brain swelling, or disruption of neurological function [15]. Additionally, tumors may be deemed
inoperable depending on their location in the brain [15,7]. After resection or biopsy, factors such
as patient’s age, performance status, and genotype should all be considered when discussing
course of treatment [16]. If the patient is deemed fit, it is advised that patients undergo systemic
therapies since infiltrating cells beyond the site of resection can further drive tumor progression,
even when gross total resection appears to be confirmed by neuroimaging [7]. The standard
approach for systemic therapy in treating glioblastoma is concurrent radiation and chemotherapy,
followed by adjuvant chemotherapy [9, 14, 16, 41]. Radiotherapy is an important modality of
treatment to improve both local control and survival, and radiation treatment with concurrent and
adjuvant TMZ treatment is the standard of care treatment for glioblastoma [14,16]. TMZ is the
standard first-line chemotherapeutic used to treat glioblastoma [15,16]. As previously mentioned,
TMZ acts by inducing DNA damage to prevent tumor proliferation [24,14]. TMZ is administered
orally with standard dosing at 75mg/m2 with concurrent radiotherapy and 150-200mg/m2 on days
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1-5 every 28 days during six cycles of adjuvant treatment [7,16]. Due to its small molecular size
and lipophilicity, TMZ is capable of penetrating the blood-brain barrier to enter the central
nervous system (CNS) [14, 27, 46]. However, despite being able to enter the CNS, the
concentration of TMZ is relatively low in brain tumor tissue – about 20% of plasma levels –
which requires that the cancers being treated are very sensitive to TMZ [27, 46]. Additionally,
there is no survival benefit to dose-intensified TMZ regimens, as higher doses are associated
with higher toxicity and reduced quality of life [16, 7, 44] Treatment with TMZ can lead to
significant side effects such as myelosuppression, especially thrombocytopenia and neutropenia,
as well as lymphopenia which is long-lasting and is associated with reduced survival and poor
response to immunologic interventions [16,27]. Unfortunately, first-line treatments often do no
prevent recurrent glioblastoma and most patients experience disease progression after a median 7
to 10-month progression-free survival period [10, 45]. Treatment options for recurrent
glioblastoma include further surgical resection, reirradiation, systemic therapies, and combined
approaches; however, there is no established standard of care for recurrent glioblastoma and
there is little evidence that current interventions prolong overall survival [16]. Although current
treatment options do offer some benefit to prolonged patient survival, further discoveries of
strategies which enhance the efficacy of these regimens are sorely needed. To this end, we were
excited at the opportunity to better understand whether the previously characterized, cell deathpromoting androgen receptor mechanism, could serve as a valuable adjuvant to the existing
chemotherapy regimen.
The goal of this current research was to further explore a novel mechanism by which a
putative membrane AR modulates cell function/viability. As noted above, our lab previously found
that ligand binding to a putative membrane AR increases cell vulnerability to two different
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cytotoxic agents, IAA and TMZ. Given that the cellular damage elicited by these two compounds
is through two distinct mechanisms, one aim of this research was to determine if the “damagepromoting” effect of ligand binding to the membrane AR is mechanism (of cytotoxicity)-specific.
If the primary mechanism of the membrane AR is to reduce intracellular anti-oxidant defenses, or
render the mitochondria more vulnerable, it is likely that ligand binding will have a significant
effect on IAA-induced cytotoxicity. Alternatively, if the major mechanism by which the membrane
AR elicits its effects is by reducing DNA repair capacity, then there may be more robust
consequences in the presence of TMZ.
We, of course, accepted the possibility that ligand binding to the membrane AR is equally
effective at enhancing cell death consequent to either IAA or TMZ. Given that engaging the
membrane AR has been shown to reduce ERK and Akt signaling, two very broadly-impacting cell
survival pathways, ligand binding may weaken cell viability signaling in such a “general” way to
render the cell vulnerable to any cytotoxic insult. Understanding the mechanism by which the
putative membrane AR facilitates changes in cell viability will help to further characterize the
function of this novel receptor, and its potential utility in targeting it to treat different diseases.
Another aim of this research was to determine if engaging the membrane AR enhances
sensitivity to cytotoxic insults in “normal”, healthy primary astrocytes, or whether the deathpromoting effects are specific to tumor cells. If the effect of engaging the membrane AR is limited
to tumor cells, this would be very exciting since it would suggest the opportunity to selectively
target cancer cells, while leaving healthy astrocytes around the tumor unscathed. This would be of
great value since most chemotherapeutic regimens promote cell death in both the target cell (i.e.,
the cancer cell) as well as other, non-cancer cells.
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As previously discussed, the current regimen for chemotherapy with TMZ often results in
prolonged systemic exposure and harsh side effects, despite relatively low concentrations of TMZ
in tumor tissue. Although chemotherapy with TMZ can significantly prolong survival, the patient’s
quality of life may deteriorate with treatment (partly due to “off-target” effects of TMZ), and
therefore the benefit of treatment is modest. Ideally, improvements to current TMZ treatment
would aim to reduce systemic toxicity, theoretically reducing side effects, and hopefully improving
patient quality of life. Should the current research provide evidence that glioblastoma cell
sensitivity to TMZ is enhanced through engaging the membrane AR, this could provide a
mechanism through which lower doses of TMZ become effective. Therefore, this current research
provides an opportunity to explore a novel mechanism by which the current standard of
glioblastoma treatment can be improved.

CHAPTER TWO
METHODOLOGIES
Cell Culture.
Rat glioma cells (C6; ATCC, Manassas, VA) are a glial cell strain cloned from a rat glial
tumor induced by N-nitrosomethylurea by Benda et al. [54, 55]. For the current research C6 cells
were grown and maintained in DMEM media without sodium pyruvate (Gibco Laboratories,
Montgomery County, MD) supplemented with 10% fetal bovine serum (FBS) and 1% PenicillinStreptomycin. TMZ-sensitive human glioblastoma cells, derived from glioblastoma in a 53-yearold male (A172; ATCC) [56, 57], were grown and maintained in DMEM media without sodium
pyruvate (Gibco) supplemented with 10% FBS and 1% Penicillin-Streptomycin. TMZinsensitive human glioblastoma cells, derived from glioblastoma multiforme in a 61-year-old
male (T98G; ATCC) [58], were grown and maintained in EMEM (ATCC) supplemented with
10% FBS and 1% Penicillin-Streptomycin. Primary astrocytes were obtained from cortical tissue
of 2-day-old mouse pups (BrainBits LLC, Springfield, IL) [59]. For the current research primary
astrocytes were grown and maintained in DMEM with sodium pyruvate (Gibco) supplemented
with 10% FBS and 1% Penicillin-Streptomycin. All cell types were maintained at 37ºC in a
humidified incubator containing 5% CO2.
24 hours before experiments, cell culture media was changed to DMEM media without
sodium pyruvate (C6; A172), EMEM media (T98G), or DMEM media with sodium pyruvate
(primary astrocytes) supplemented with 10% charcoal-stripped FBS (CS-FBS) and 1%
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Penicillin-Streptomycin. Charcoal-stripped FBS was used to avoid the potential confound of
endogenous steroid hormones that may be present in non-charcoal stripped FBS. For
experiments, cells were plated on black-wall, clear bottom 96-well plates one day prior to
treatment at a concentration of 10,000 cells per well.
Treatment of Cells with IAA.
To evaluate the cytotoxic effects of Iodoacetic Acid (IAA; Sigma-Aldrich, St. Louis,
MO) cells were treated with either vehicle control (CS-FBS media) or IAA [1uM, 3uM, 10uM,
30uM, 100uM] for 6 hours to assess dose response and generate an EC50 value for IAA.
Treatment of Cells with IAA and T-BSA.
Once an EC50 value was obtained for IAA, cells were treated with either vehicle control
(CSFBS media), or co-application of IAA [EC50 value, which was ~10uM] and Testosterone (T)3-(O-carboxy-methyl)oxime: BSA (T-BSA; Steraloids Inc., Newport RI) [0.5uM, 1.0uM, 10uM]
for 6 hours to assess the effects of cytotoxic insult and androgens on cell viability. These
concentrations of T-BSA were based on prior work conducted in the Singh lab, and derived from
considerations of both noted efficacy and solubility constraints of the compound. Additional
control groups included IAA alone [10uM], T-BSA [0.5uM, 1.0uM, 10uM] alone, and Bovine
Serum Albumin (BSA; Sigma-Aldrich, St. Louis, MO) [10uM] (control for T-BSA). 100uM IAA
was included as a positive control, noting that this concentration of IAA kills approximately
100% of the cells.
Treatment of Cells with TMZ.
To evaluate the cytotoxic effects of the chemotherapeutic Temozolomide (TMZ; SigmaAldrich, St. Louis, MO), cells were treated with either vehicle control (CS-FBS media) or TMZ
[0.1mM, 0.25mM, 0.35mM, 0.45mM, 0.6mM, 0.75mM, 1mM, 5mM] for 48 hours to assess
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concentration-response curve and generate EC30 and EC50 values for TMZ. Our lab has shown a
relative EC50 for TMZ in TMZ-sensitive human glioblastoma at approximately 500uM; notably,
500uM TMZ has relevant equivalence to the dose administered clinically to patients at
200mg/m2 [22]. We chose to look at the EC30 concentration is to assess whether lower doses of
TMZ have increased efficacy under conditions where a presumed ligand for the membrane AR
(i.e. T-BSA) is also present.
Co-Treatment of Cells of TMZ and T-BSA.
Based on the obtained EC30 and EC50 values for TMZ, cells were treated with either
vehicle control (CSFBS media), or the co-application of TMZ (Sigma-Aldrich) at EC30 and EC50
concentrations [0.2mM; 0.5mM] and T-BSA (Steraloids Inc.) [0.1uM, 1.0uM, 10uM] for 48
hours to assess the effects of cytotoxic insult and androgens on cell viability. Additional control
groups included TMZ [0.2mM, 0.5mM] alone, T-BSA [0.1uM, 1.0uM, 10uM] alone, and BSA
alone (Sigma-Aldrich) [10uM] (control for T-BSA). 5mM TMZ was also included as a positive
control, noting that this concentration of TMZ kills approximately 100% of the cells.
Treatment of Cells with TMZ and T-BSA Pre-Treatment.
To assess the effect of “priming” the cells by binding to the putative membraneassociated androgen receptor (mAR), cells were initially treated with T-BSA [0.1uM, 1.0uM,
10uM] for 24 hours, followed by application of TMZ [0.2mM, 0.5mM] for an additional 24
hours. Control groups included TMZ alone [0.2mM, 0.5mM], T-BSA alone [0.1uM, 1.0uM,
10uM], BSA alone [10uM] (control for T-BSA), and 5mM TMZ (as the positive “kill” control).
Cell Viability Assay.
After treatment with the above-referenced compounds for the specified times, cell
viability was assessed by using the Live/Dead Viability/Cytotoxicity Kit from Invitrogen
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(Invitrogen, Carlsbad, CA) which includes two components, calceinAM and EthD-1; the assay
was conducted according to the manufacturer’s instructions. Following the specified cell
treatments, for the specified duration, media was removed, and cells were washed with 250uL of
PBS. To create the working solutions for the cell viability assay, 20uL of the supplied 2mM
EthD-1 stock solution was added to 10mL PBS and mixed thoroughly, giving an approximately
4uM EthD-1 working solution. 5uL of the supplied 4mM calceinAM stock solution was then
added to the 10mL EthD-1 solution and mixed thoroughly, yielding an approximately 2uM
calcein AM and 4uM EthD-1 working solution. 100uL of fresh PBS was then added to each well,
followed by the application of 100uL of the calceinAM and EthD-1 working solution to each
well, yielding a final volume of 200uL per well, containing a final concentration of 1uM
calceinAM and 2uM EthD-1. The plate was then incubated at 37ºC in a humidified incubator
containing 5% CO2 for 30 minutes. Fluorescence was measured at an excitation wavelength of
485nm and emission wavelength of and 530nm for calceinAM, and 530nm excitation and 645nm
emission wavelengths for EthD-1.
Statistical Analysis.
Raw fluorescence values were first normalized to the control/baseline levels, yielding
data represented as “percent of control”. The data from at least three independent experiments
were then analyzed (each experiment representing an “n” of 1) using an analysis of variance
(ANOVA), followed by a Tukey’s post hoc analysis to assess group differences. The data were
presented in a bar graph depicting the mean ± S.E.M (GraphPad Software, San Diego, CA).
Statistical significance was inferred if the probability of a Type I error (“false positive”, a, was
less than 0.05 (i.e., p <0.05). Each experiment was conducted a minimum of three separate times.
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CHAPTER THREE
RESULTS
C6 Cells are Responsive to Iodoacetic Acid (IAA).
As an initial step to establish the experimental model, we determined the concentration of
IAA required to elicit approximately 50% cell death. Using the calcein AM assay as an indicator
of cell viability, a concentration-response curve was generated for IAA, following 6 hr treatment,
in C6 cells (Fig. 1). This duration of treatment was based on prior work conducted and published
by the Singh lab [20, 21]. The data revealed an effective concentration (EC50) of approximately
10uM, which was used in subsequent experiments.
T-BSA Enhances the Cytotoxic Effect of IAA in C6 Cells.
In C6 cells, treatment with 10uM IAA alone for 6 hours significantly reduced cell
viability (to 59.5% viable cells) compared to the vehicle control (consisting of 10% charcoalstripped fetal bovine serum (CSFBS) containing media), whose viability was set at 100%)
(p<0.0001) (Fig. 2). The application of 10uM T-BSA along with 10uM IAA resulted in a further
decrease in cell viability (down to 15.8%) relative to cells treated with 10uM IAA alone
(p<0.0001). Co-treatment of 0.5uM T-BSA or 1uM T-BSA with 10uM IAA, however, did not
show significant change in cell viability compared to cells treated with 10uM IAA alone,
suggesting that the effect was concentration dependent. Treatment with T-BSA alone at any of
the concentrations tested [0.5uM, 1uM, or 10uM] did not have any significant effect on cell
viability compared to the vehicle control. Neither treatment with 10uM BSA alone, nor co-
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treatment of 10uM BSA with 10uM IAA had any significant effect on cell viability compared to
vehicle control.
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Figure 1. Concentration-Response for IAA-Induced Cytotoxicity in C6 Cells. C6 cells were
plated at 10,000 cells/well 24 hrs prior to treatment with IAA (6hr). C6 cells showed a
concentration-dependent response to IAA where the half maximal effective concentration (EC50)
to elicit cytotoxicity was 11.91uM. Cell viability was assessed using a calceinAM assay (n=3).
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Figure 2. T-BSA Enhances the Cytotoxic Effect of IAA in C6 Cells. C6 cells were plated at
10,000 cells/well 24 hrs prior to treatment. Cells were co-treated with IAA and T-BSA for 6hrs.
Treatment with 10uM IAA alone significantly reduced cell viability compared to the vehicle
control (10% CSFBS media) after 6 hrs (p<0.0001). Co-treatment of 10uM T-BSA with 10uM
IAA showed significantly greater reduction in cell viability compared to treatment with IAA
alone (p<0.0001). In contrast, co-treatment of IAA with the lower concentrations of 0.5uM TBSA and 1uM T-BSA did not enhance IAA-induced cell death. Treatment with T-BSA alone did
not have any significant effect on cell viability. 100 uM IAA was used as a positive control for
maximal cell death, while the 10uM BSA alone group served as the control for TBSA
application. Cell viability was assessed using a calceinAM assay. Data were normalized to
vehicle control which is set at 100% (n=4). ****: p< 0.0001
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C6 Cells are Responsive to Temozolomide (TMZ).
As conducted with IAA, prior to determining whether T-BSA influenced the cell deathpromoting effects of the chemotherapeutic, TMZ, we determined the concentration of TMZ
required to elicit approximately 50% cell death in C6 cells. As in all our experiments, the calcein
AM assay was used to gauge cell viability. The concentration-response curve generated for TMZ
in C6 cells following 48 hr treatment (a time point used previously by the Singh lab) revealed a
half maximal effective concentration (EC50) of approximately 900uM (Fig. 3) and was used in
subsequent experiments.
T-BSA Enhances the Cytotoxic Effect of IAA in C6 Cells.
In C6 cells, treatment with 900uM TMZ alone significantly reduced cell viability (to
67%) compared to the vehicle control (comprised of 10% CSFBS media) (100%) after 48 hours
(p<0.0001) (Fig. 4). Co-treatment of 10uM T-BSA with 900uM TMZ enhanced the cytotoxic
effects of TMZ alone to 45% viable cells (p<0.0001). Neither co-treatment of 0.1uM or 1uM TBSA with 900uM TMZ significantly changed cell viability compared to cells treated with
900uM TMZ alone. Treatment with 10uM T-BSA alone significantly decreased cell viability
(75%) compared to vehicle control, although this effect appeared to be inconsistent within C6
cells. Treatment with 0.1uM or 1uM T-BSA alone did not have any significant effect on cell
viability. While in these particular studies, 10uM BSA alone showed a modest, but statistically
significant, decrease in cell viability (to 89.2% of control) compared to the vehicle control; 10uM
BSA did not alter the effect of TMZ.
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Figure 3. Concentration-Response for TMZ-Induced Cytotoxicity in C6 Cells. C6 cells were
plated at 10,000 cells/well one day prior to treatment with TMZ (48hr). C6 cells showed a
concentration-dependent response to TMZ where the half maximal effective concentration
(EC50) required to elicit cell death was approximately 0.988mM. Cell viability was assessed
using a calceinAM assay (n=3).
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Figure 4. T-BSA Enhances the Cytotoxic Effects of TMZ in C6 Cells. C6 cells were plated at
10,000 cells/well one day prior to treatment. Cells were co-treated with TMZ and T-BSA for
48hrs. Treatment with 900uM TMZ alone significantly reduced cell viability compared to the
vehicle control (10% CSFBS media) after 48 hrs (p<0.001). Co-treatment of 10uM T-BSA with
900uM TMZ showed significant enhancement of decreased cell viability compared to treatment
with TMZ alone (p<0.0001). Co-application of either 0.1uM T-BSA or 1uM T-BSA with 900uM
TMZ did not significantly decrease cell viability relative to TMZ treatment alone. Treatment
with 10uM T-BSA alone significantly decreased cell viability, whereas treatment with 0.1uM or
1uM T-BSA alone did not have any significant effect on cell viability. 5mM TMZ served as a
positive control for maximal cell death, while the 10uM BSA alone group served as the control
for TBSA application. Cell viability was assessed using a calceinAM assay. Data were
normalized to vehicle control which is set at 100% (n=3). ****: p<0.0001
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A172 Cells are Responsive to TMZ.
Figure 5 shows the results of our concentration response analysis for TMZ in A172 cells.
The analysis confirms that A172 cells are responsive to TMZ after a 48-hour treatment and
revealed a half maximal effective concentration (EC50) of approximately 500uM. In an effort to
determine if sublethal concentrations of TMZ could also be augmented by T-BSA in subsequent
experiments, the EC30 values were also determined and served as the basis for subsequent
experiments. The EC30 value was found to be approximately 200uM.
T98G Cells are Responsive to TMZ.
Figure 6 shows the results of our concentration response analysis for TMZ in the
chemotherapy insensitive cell line, T98G. Following the conduct of a concentration response
analysis for TMZ in T98G cells, we determined the half maximal effective concentration (EC50)
to be approximately 750uM, with the EC30 being approximately 300uM. This relatively higher
EC50 (and EC30) values are consistent with the literature that suggests the T98G cells are less
sensitive to TMZ [24, 25, 47].
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Figure 5. Concentration-Response for TMZ-Induced Cytotoxicity in A172 Cells. A172
glioblastoma cells were plated at 10,000 cells/well 24 hrs prior to treatment with TMZ (48hr).
A172 cells showed a concentration-dependent response to TMZ where the half maximal
effective concentration (EC50) required to elicit cytotoxicity was 0.599mM and EC30=0.256mM.
Cell viability was assessed using a calceinAM assay (n=3).
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Figure 6. Concentration-Response for TMZ-Induced Cytotoxicity in Chemotherapy
Resistant T98G Cells. T98G cells were plated at 10,000 cells/well one day prior to treatment
with TMZ (48hr). T98G cells showed a concentration-dependent response to TMZ where the
half maximal effective concentration (EC50) to elicit cytotoxicity was 0.756mM and
EC30=0.324mM. Cell viability was assessed using a calceinAM assay (n=4).
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T-BSA Does Not Enhance the Cytotoxic Effect of TMZ in A172 Cells When Administered
Together.
In A172 cells, treatment with the EC30 concentration of TMZ (200uM) alone did not have
an effect on cell viability, whereas treatment with 500uM of TMZ alone significantly decreased
cell viability (to 54.5% of control) (Fig. 7). Neither 0.1uM, 1uM, nor 10uM T-BSA when coapplied with either 200uM or 500uM TMZ significantly altered cell viability compared to cells
treated with either 200uM or 500uM TMZ alone, which supports the conclusion that binding to
the putative membrane AR does not augment cytotoxicity of the chemotherapeutic when coadministered. In these studies, treatment with T-BSA alone at any of the tested concentrations
[0.1uM, 1uM, 10uM] showed no significant effect on cell viability compared to the vehicle
control. 10uM BSA when administered alone did not have any influence on cell viability.
Moreover, 10uM BSA did not alter the effect of either 200uM or 500uM TMZ when
administered alone.
T-BSA Does Not Enhance the Cytotoxic Effect of TMZ in T98G Cells When Administered
Together.
Figure 8 shows that in the chemotherapeutic (TMZ) resistant T98G cells, treatment with
200uM of TMZ alone did not have an effect on cell viability, whereas treatment with 500uM of
TMZ alone significantly decreased cell viability (to 66.8% of control). Neither concentrations of
T-BSA (0.1uM, 1uM, or 10uM) altered the effects of either 200uM or 500uM TMZ. As noted in
the A172 cells, there was also no discernable effect when cells were treated with T-BSA alone, at
any of the concentrations tested [0.1uM, 1uM, 10uM]. The osmolarity-based control (to account
for the bulky BSA molecule associated with testosterone molecules) for T-BSA (10uM BSA)
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also did not have an effect, either when administered by itself or when co-applied with 200uM or
500uM TMZ.
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Figure 7. T-BSA Does Not Enhance TMZ-induced Cytotoxicity in A172 Cells When
Administered Together. A172 cells were plated at 10,000 cells/well 24 hrs prior to treatment,
after which the cells were treated with both TMZ and T-BSA (co-application) for 48hrs.
Treatment with 200uM of TMZ alone did not have an effect on cell viability, whereas treatment
with 500uM of TMZ alone significantly decreased cell viability compared to the vehicle control
(10% CSFBS media) after 48 hrs (p<0.0001). Cells co-treated with T-BSA and TMZ, however,
did not result in any further decline in cell viability compared to cells treated with TMZ alone.
Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not have any significant effect on cell
viability. Co-treatment of 10uM BSA, the osmolarity-based control for T-BSA, with 500uM
TMZ did not alter the effect of TMZ alone. 5mM TMZ served as a positive control for maximal
cell death, while the 10uM BSA alone group served as the control for TBSA application. Cell
viability was assessed using a calceinAM assay. Data were normalized to vehicle control, which
is set at 100% (n=3). ****: p<0.0001
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Figure 8. T-BSA Does Not Enhance TMZ-induced Cytotoxicity in T98G Cells When
Administered Together. T98G cells were plated at 10,000 cells/well 24 hrs prior to treatment,
after which the cells were treated with both TMZ and T-BSA (co-application) for 48hrs.
Treatment with 200uM of TMZ alone did not have an effect on cell viability, whereas treatment
with 500uM of TMZ alone significantly decreased cell viability compared to the vehicle control
(10% CSFBS media) after 48 hrs (p<0.0001). Co-treatment of either 0.1, 1, or 10uM T-BSA
with either 200uM or 500uM TMZ did not significantly affect cell viability compared to cells
treated with 200uM or 500uM TMZ alone. Treatment with T-BSA alone, at either 0.1, 1 or 10
uM, did not have any significant effect on cell viability. 5mM TMZ served as a positive control
for maximal cell death, while the 10uM BSA alone group served as the control for TBSA
application. Cell viability was assessed using a calceinAM assay. Data were normalized to
vehicle control which is set at 100% (n=3). ****: p< 0.0001
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Pre-treatment of T-BSA Does Not Affect Cell Viability Consequent to 24hr TMZ
Treatment in A172 Cells.
We surmised that co-application of the membrane AR ligand (T-BSA) with the
chemotherapeutic may not give the compound sufficient time to elicit the appropriate cell deathsensitizing effects and thus, “set the stage”, for enhanced vulnerability to TMZ. As such, we
tested whether pre-treatment with T-BSA would be more likely to augment the cytotoxicity (or
sensitize) the human glioblastoma cell models to TMZ. And whereas the concentration response
analysis for the effect of TMZ on A172 cells used the paradigm of 48 hr exposure to TMZ, we
chose to also evaluate the impact of T-BSA pretreatment on A172 cells treated for a shorter
duration of time with TMZ (i.e., 24 hrs). In subsequent experiments, we also evaluated the effect
of T-BSA pre-treatment on the “usual” 48hr treatment with TMZ.
Figure 9 reveals that in A172 cells, treatment with 200uM or 500uM TMZ alone did not affect
cell viability compared to the vehicle control after 24hrs (Fig. 9), a result that wasn’t entirely
unexpected since prior (unpublished) work from the Singh lab revealed that the ideal time point
for TMZ to elicit cell death was 48 hr post treatment. However, we initially hypothesized that the
T-BSA might sensitize the cells to TMZ such that its cytotoxic effects could be noticeable even
at shorter periods of (TMZ) treatment. The data showed that pre-treatment with T-BSA does not
enhance the effect of TMZ (or sensitize the cells to TMZ). Cells that were pre-treated with TBSA [0.1uM, 1uM, 10uM] for 24 hours prior to being treated with either 200uM or 500uM TMZ
for an additional 24 hours showed no significant change in cell viability compared to cells
treated with either 200uM or 500uM TMZ alone. While cells treated with 0.1uM and 10uM TBSA alone showed no significant effect on cell viability compared to the vehicle control,
treatment with 1uM T-BSA alone showed fluorescence values that were statistically higher than
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the vehicle control (p<0.005), the basis for which is not clear and will require further
investigation. Neither treatment with 10uM BSA alone, nor co-treatment of 10uM BSA with
200uM TMZ or 500uM showed significant effect on cell viability compared to control.
Pre-Treatment with T-BSA Failed to Augment TMZ-Induced Cytotoxicity in A172 Cells.
In an effort to be consistent with the “ideal” duration of TMZ treatment, we extended our
pre-treatment paradigm analysis to include 48 hr post-TMZ treatment. In this situation, we noted,
as in prior experiments, that only the 500uM concentration of TMZ resulted in a statistically
significant decrease in cell viability (to 56.7% of control, Fig. 10). Through statistical analysis of
group differences, we did, however, find that cells pre-treated with 1uM T-BSA for 24 hours
prior to being treated with 200uM TMZ for an additional 48 hours showed significant increase in
cell viability compared to cells treated with 200uM TMZ alone. But since the 200uM TMZ alone
group was not statistically different from the vehicle treated control, we suggest that this result
should not be over-interpreted, but rather, the significant “protective” effect seen in this
treatment condition is more likely a statistical anomaly, rather than a true protective effect of TBSA. Treatment with T-BSA alone [0.1uM, 1uM, 10uM] showed no significant effect on cell
viability compared to the vehicle control. Furthermore, and consistent with other experiments,
treatment with 10uM BSA alone had no effect on cell viability, either when administered alone
or in conjunction with TMZ.
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Figure 9. Pre-treatment of T-BSA Does Not Affect Cell Viability Consequent to 24hr TMZ
Treatment in A172 Cells. A172 cells were plated at 10,000 cells/well 24 hrs prior to treatment.
A172 cells were initially treated with T-BSA at various concentrations for 24hrs before being
additionally treated with 200uM or 500uM TMZ for 24hrs. Cells treated with TMZ alone
showed no significant decrease in cell viability 24hrs after treatment compared to vehicle control
(10% CSFBS media). Pre-treatment with T-BSA [0.1uM, 1uM, 10uM] for 24 hrs prior to being
treated with either 200uM or 500uM TMZ for an additional 24 hrs showed no significant change
in cell viability. Cells treated with 0.1uM and 10uM T-BSA alone showed no significant effect
on cell viability compared to the vehicle control, whereas treatment with 1uM T-BSA alone
showed a significant increase in cell viability compared to the vehicle control (p<0.005). 5mM
TMZ served as a positive control for maximal cell death, while the 10uM BSA alone group
served as the control for TBSA application. Cell viability was assessed using a calceinAM assay.
Data were normalized to vehicle control which is set at 100% (n=3). **: p<0.005
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Figure 10. T-BSA Does Not Enhance A172 Cell Death Elicited by 48hr TMZ. A172 cells
were plated at 10,000 cells/well 24 hrs prior to treatment. A172 cells were initially treated with
T-BSA at various concentrations for 24hrs before treatment with either 200uM or 500uM TMZ,
in the continued presence of T-BSA, for an additional 48hrs. Treatment with 200uM TMZ did
not affect cell viability compared to the vehicle control (10% CSFBS media), whereas treatment
with 500uM TMZ showed significant decrease in cell viability compared to the vehicle control
after 48hrs (p<0.001). Cells pre-treated with 1uM T-BSA showed significant increase in cell
viability following treatment with 200uM TMZ after 48hrs, compared to cells treated with
200uM TMZ alone (p<0.005). Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not
have any significant effect on cell viability. 5mM TMZ served as a positive control for maximal
cell death, while the 10uM BSA alone group served as the control for TBSA application Cell
viability was assessed using a calceinAM assay. Data were normalized to vehicle control which
is set at 100% (n=3). ns: no significance; **: p<0.005; ***: p<0.001
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Pre-Treatment of T-BSA Followed by 24hr Treatment with TMZ Enhances the Cytotoxic
Effect of TMZ in T98G Cells.
We extended the analysis of T-BSA pretreatment to the T98G cells. We found that while
treatment of cells with 500uM TMZ showed a modest, though statistically significant, decrease
in cell viability (86.2% of control) compared to the vehicle control after 24hrs (p<0.05), pretreatment with T-BSA [0.1uM, 1uM, 10uM] for 24 hours prior to 500uM TMZ (for an additional
24 hours) showed significant enhancement of cytotoxicity (59.8%, 69.5%, and 65.6% of control,
respectively for 0.1, 1 and 10uM T-BSA) compared to cells treated with 500uM TMZ alone
(Figure 11). In contrast, pre-treatment with T-BSA did not alter the effect of 200uM TMZ.
Neither treatment with T-BSA alone [0.1uM, 1uM, 10uM] of 10uM BSA alone showed any
effect on cell viability.
Pre-Treatment of T-BSA Followed by 48hr Treatment with TMZ Does Not Enhance the
Cytotoxic Effect of TMZ in T98G Cells.
As done with A172 cells, we also evaluated the effect of T-BSA pre-treatment on the
effect of 48 hr TMZ treatment in T98G cells. Whereas treatment with 500uM TMZ showed a
significant decrease in cell viability (67.2%) compared to the vehicle control after 48hrs
(p<0.0001) (Fig. 12), cells pre-treated with T-BSA [0.1uM, 1uM, 10uM] for 24 hours did not
enhance the effect of either the 200 uM or 500uM concentrations of TMZ.
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Figure 11. Pre-treatment With T-BSA Enhances the Cytotoxic Effect of TMZ in T98G
Cells. T98G cells were plated at 10,000 cells/well 24 hrs prior to treatment. T98G cells were
initially treated with T-BSA at various concentrations for 24hrs followed by treatment with
200uM or 500uM TMZ for an additional 24hrs, in the continued presence of T-BSA. Treatment
with 200uM TMZ did not affect cell viability compared to the vehicle control (10% CSFBS
media), whereas treatment with 500uM TMZ showed a statistically significant, decrease in cell
viability compared to the vehicle control after 24hrs (p<0.05). Pre-treatment with T-BSA
significantly enhanced the decrease in cell viability compared to 500uM TMZ alone (p<0.0001;
p<0.005; p<0.0001). Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not have any
significant effect on cell viability. 5mM TMZ served as a positive control for maximal cell death,
while the 10uM BSA alone group served as the control for TBSA application. Cell viability was
assessed using a calceinAM assay. Data were normalized to vehicle control which is set at 100%
(n=3). *: p<0.05; **: p<0.005; ****: p<0.0001
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Figure 12. Pre-treatment With T-BSA Does Not Enhance the Cytotoxic Effect of TMZ
After 48hrs in T98G Cells. T98G cells were plated at 10,000 cells/well 24 hrs prior to
treatment. T98G cells were initially treated with T-BSA at various concentrations for 24hrs
before being additionally treated with 200uM or 500uM TMZ for 48hrs. Treatment with 200uM
TMZ did not affect cell viability compared to the vehicle control (10% CSFBS media), whereas
treatment with 500uM TMZ showed a significant decrease in cell viability compared to the
vehicle control after 48hrs (p<0.0001). Pre-treatment with T-BSA did not alter the effects of
TMZ on cell viability. Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not have any
significant effect on cell viability. 5mM TMZ served as a positive control for maximal cell death,
while the 10uM BSA alone group served as the control for TBSA application. Cell viability was
assessed using a calceinAM assay. Data were normalized to vehicle control which is set at 100%
(n=3). ****: p<0.0001
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A172 Cells are Responsive to IAA.
While the gold standard chemotherapeutic used in the treatment of glioblastoma is TMZ,
we wanted to determine if the modest (or lack of) effect of T-BSA was attributed to the type of
insult, noting that T-BSA robustly enhanced the cytotoxicity of the metabolic/oxidative insult,
IAA, in C6 glioma cells. As in prior experiments, we first conducted a concentration response
analysis for IAA in A172 cells (Fig. 13). The data demonstrate that A172 cells are indeed
responsive to IAA, after a 6-hour treatment, with the half maximal effective concentration (EC50)
required to elicit cytotoxicity being approximately 75uM. This concentration was used for
subsequent experiments where IAA was applied to A172 cells.
T-BSA Does Not Enhance the Cytotoxic Effect of IAA in A172 Cells.
In A172 cells, treatment with 75uM IAA alone, for 6 hrs, significantly decreased cell
viability (46%) compared to vehicle control (p<0.0001) (Fig. 14). Co-treatment of T-BSA
[0.1uM, 1uM, 10uM] with 75uM IAA did not significantly affect cell viability compared to cells
treated with 75uM IAA alone. As noted in previous experiments, treatment with 10uM BSA
alone did not affect cell viability compared to vehicle control, and nor did it alter the effect of
IAA.
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Figure 13. Concentration-Response for IAA-Induced Cytotoxicity in A172 cells. A172 cells
were plated at 10,000 cells/well 24 hrs prior to treatment with IAA (6hr). A172 cells showed a
concentration-dependent response to IAA where the half maximal effective concentration (EC50)
to promote cell death was 74.24uM. Cell viability was assessed using a calceinAM assay (n=5).

37
✱✱✱✱
✱✱✱✱

Cell Viability
(% of control)

150

✱

100

50

Ve
0.
hi
1u
cl
e
M
TB
1u
SA
M
10 TB
uM SA
75
uM
TB
IA
75 SA
A
75
uM
uM + 0
.
I
IA 1uM AA
75
uM A
T
+
1u BS
IA
A
A
M
+
T
B
10
uM SA
10
TB
uM
1
S
0
B
SA uM A
B
+
75 SA
uM
I
5m AA
M
IA
A

0

Figure 14. T-BSA Does Not Enhance the Cytotoxic Effect of IAA in A172 Cells. A172 cells
were plated at 10,000 cells/well 24 hrs prior to treatment. Cells were co-treated with IAA and TBSA for 6hrs. Treatment with 75uM IAA alone significantly decreased cell viability compared
to vehicle control (10% CSFBS media) after 6hrs (p<0.001). Co-treatment with T-BSA and
75uM IAA did not result in greater cell death relative to that elicited by IAA alone. Cells treated
with 0.1uM T-BSA alone significantly increased cell viability compared to the vehicle control
(p<0.05), whereas treatment with 1uM or 10uM T-BSA alone did not significantly affect cell
viability compared to the vehicle control. Co-treatment of 10uM BSA with 75uM IAA
significantly decreased cell viability compared to vehicle control (p <0.0001). 5mM IAA served
as a positive control for maximal cell death, while the 10uM BSA alone group served as the
control for TBSA application. Cell viability was assessed using a calceinAM assay. Data were
normalized to vehicle control which is set at 100% (n=3). *: p<0.05; ****: p<0.0001
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T98G Cells are Responsive to IAA.
As conducted with A172 cells, we also determined the concentration response of T98G
cells to IAA (Fig. 15). The data verifies that T98G cells are also responsive to IAA after a 6-hour
treatment with the half maximal effective concentration (EC50) required to elicit cell death as
being approximately 80uM.
Co-Treatment of T-BSA with IAA Increases Cell Viability in T98G Cells.
In T98G cells, treatment with 75uM IAA alone failed to elicit a reduction in cell viability
compared to vehicle control after 6hrs (Fig. 16). Given that T98G cells are relatively resistant to
TMZ, these data may suggest that T98G cells have enhanced cell-survival associated
mechanisms in place that render them more resistant to cytotoxic insult, more generally.
Alternatively, the narrow concentration response range noted in Figure 15 may suggest that even
though 75uM was close to the EC50 value of ~80uM, we may have ended up with a sublethal
concentration of IAA. Nevertheless, we proceeded with this concentration to determine whether
treatment with T-BSA might alter the effect of a sublethal concentration of IAA and transform it
into a cytotoxic effect. We found that neither concentration of T-BSA, when applied
concomitantly with IAA, resulted in a reduction in cell viability.
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Figure 15. Concentration-Response for IAA-Induced Cytotoxicity in T98G cells. T98G cells
were plated at 10,000 cells/well 24 hrs prior to treatment with varying concentrations of IAA
(6hr). T98G cells showed a concentration-dependent response to IAA where the half maximal
effective concentration (EC50) is 83.81uM. Cell viability was assessed using a calceinAM assay
(n=5).
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Figure 16. Co-Treatment of T-BSA and IAA Does Not Enhance the Effect of IAA Alone in
T98G Cells. T98G cells were plated at 10,000 cells/well 24 hrs prior to treatment. Treatment
with 75uM IAA alone does not affect cell viability compared to vehicle control (10% CSFBS
media) after 6hrs Cells co-treated with T-BSA and 75uM IAA showed significant increases in
cell viability compared to cell treated with 75uM IAA alone (p<0.0001; p<0.0001; p<0.005).
Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not have any significant effect on cell
viability. 5mM IAA served as a positive control for maximal cell death, while the 10uM BSA
alone group served as the control for TBSA application. Cell viability was assessed using a
calceinAM assay. Data were normalized to vehicle control which is set at 100% (n=3). **:
p<0.005; ****: p<0.0001
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Primary Astrocytes are Responsive TMZ.
A key question this thesis poses is whether any effects of T-BSA also occur in “healthy”
(i.e., non-tumor) astrocytes. As conducted in prior experiments, in other cells and using different
cytotoxic agents, we first conducted a concentration-response analysis for the effect of TMZ in
primary astrocytes (Fig. 17). The concentration response verifies that primary astrocytes were
indeed responsive to TMZ after a 48-hour treatment with the half maximal effective
concentration (EC50) required to elicit cell death being approximately 475uM and the EC30 being
approximately 200uM.
Co-Treatment of 1uM T-BSA Enhances the Cytotoxic Effect of 200uM TMZ in Primary
Astrocytes.
In primary astrocytes, treatment with 200uM of TMZ alone did not have an effect on cell
viability, whereas treatment with 500uM of TMZ alone significantly decreased cell viability
(78.8%) compared to the vehicle control after 48 hours (p<0.0001) (Fig. 18). Co-treatment of
1uM T-BSA with 200uM TMZ showed a modest, though statistically significant, decrease in cell
viability (82.2%) compared to cells treated with 200uM TMZ alone (p<0.005). Co-treatment of
0.1uM or 10uM T-BSA, however, together with 200uM TMZ did not significantly affect cell
viability compared to cells treated with 200uM TMZ alone. Co-treatment of T-BSA [0.1uM,
1uM, 10uM] with 500uM TMZ did not significantly affect cell viability compared to cells
treated with 500uM TMZ alone.
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Figure 17. Concentration-Response for TMZ-Induced Cytotoxicity in Primary Astrocytes.
Primary astrocytes were plated at 10,000 cells/well 24 hrs prior to treatment with TMZ (48hr).
Primary astrocytes showed a concentration-dependent response to TMZ where the half maximal
effective concentration (EC50) required to elicit cytotoxicity was 0.476mM and EC30=0.204mM.
Cell viability was assessed using a calceinAM assay (n=3).
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Figure 18. T-BSA Modestly Enhanced the Cytotoxic Effect of 200uM TMZ in Primary
Astrocytes. Primary astrocytes were plated at 10,000 cells/well 24 hrs prior to treatment,
followed by co-application of both TMZ and T-BSA for 48hrs. Treatment with 200uM of TMZ
alone did not have an effect on cell viability, whereas treatment with 500uM of TMZ alone
significantly decreased cell viability compared to the vehicle control (10% CSFBS media) after
48 hrs (p<0.0001). Cells co-treated with 1uM T-BSA and 200uM TMZ showed significant
decrease in cell viability compared to treatment with 200uM TMZ alone (p<0.005). Co-treatment
of 0.1uM or 10uM T-BSA with 200uM TMZ did not significantly affect cell viability compared
to cells treated with 200uM TMZ alone. Co-treatment of T-BSA [0.1uM, 1uM, 10uM] with
500uM TMZ did not significantly affect cell viability. Co-treatment of 10uM BSA with 500uM
TMZ showed significant decrease in cell viability compared to the vehicle control (p<0.0001).
5mM TMZ served as a positive control for maximal cell death, while the 10uM BSA alone group
served as the control for TBSA application. Cell viability was assessed using a calceinAM assay.
Data were normalized to vehicle control which is set at 100% (n=3). **: p<0.005; ****:
p<0.0001
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Pre-Treatment of T-BSA Followed by 24hr Treatment with TMZ Does Not Affect Cell
Viability in Primary Astrocytes.
In primary astrocytes, treatment with 200uM or 500uM TMZ alone did not affect cell
viability compared to the vehicle control after 24hrs (Fig. 19), in contrast to that noted following
48 hr TMZ treatment (Fig. 18). Pre-treatment with T-BSA, using either of the concentrations
tested (0.1, 1 or 10uM) failed to influence the effects of TMZ. Although the following data
supports the hypothesis that T-BSA does not enhance the cytotoxic effects of TMZ in “normal”
astrocytes, it is again with the caveat that TMZ did not elicit cytotoxic effects after 24 hours.
Pre-Treatment of T-BSA Followed by 48hr Treatment with TMZ Does Not Enhance the
Cytotoxic Effect of TMZ in Primary Astrocytes.
In primary astrocytes, treatment with 200uM TMZ did not affect cell viability compared
to the vehicle control after 48hrs, whereas treatment with 500uM TMZ showed a significant
decrease in cell viability (52.4%) compared to the vehicle control (100%) after 48hrs (p<0.0001)
(Fig. 20), consistent with what we describe above, in that 500uM TMZ for 48hr is the
concentration and duration of treatment at which we see consistent cytotoxicity in most cell types
studied. In these experiments, cells that were pre-treated with T-BSA [0.1uM, 1uM, 10uM] for
24 hours prior to being treated with 500uM TMZ for an additional 48 hours showed no
significant decreases in cell viability compared to cells treated with 500uM TMZ alone. These
results suggest that T-BSA does not promote cytotoxicity in primary (“healthy”) healthy
astrocytes.
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Figure 19. Pre-treatment With T-BSA Does Not Affect Cell Viability After 24hrs in
Primary Astrocytes. Primary astrocytes were plated at 10,000 cells/well 24 hrs prior to
treatment. Primary astrocytes were initially treated with T-BSA at various concentrations for
24hrs before being additionally treated with 200uM or 500uM TMZ for 24hrs. Cells treated with
TMZ alone showed no significant decrease in cell viability 24hrs after treatment compared to
vehicle control (10% CFBS media). Pre-treatment with T-BSA did not alter the effects of TMZ
on cell viability. Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not have any
significant effect on cell viability. 5mM TMZ served as a positive control for maximal cell death,
while the 10uM BSA alone group served as the control for TBSA application. Cell viability was
assessed using a calceinAM assay. Data were normalized to vehicle control which is set at 100%
(n=3).
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Figure 20. Pre-treatment With T-BSA Does Not Enhance the Cytotoxic Effect of TMZ in
Primary Astrocytes. Primary astrocytes were plated at 10,000 cells/well 24 hrs prior to
treatment. Primary astrocytes were initially treated with T-BSA at various concentrations for
24hrs, followed by treatment with 200uM or 500uM TMZ for an additional 48hrs, in the
continued presence of T-BSA. Treatment with 200uM TMZ did not affect cell viability
compared to the vehicle control (10% CSFBS media), whereas treatment with 500uM TMZ
showed a significant decrease in cell viability compared to the vehicle control after 48hrs
(p<0.0001). Pre-treatment with T- BSA did not alter the effects of TMZ on cell viability. Cotreatment of 10uM BSA with 500uM TMZ showed significant decrease in cell viability
compared to the vehicle control. Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not
have any significant effect on cell viability. 5mM TMZ served as a positive control for maximal
cell death, while the 10uM BSA alone group served as the control for TBSA application. Cell
viability was assessed using a calceinAM assay. Data were normalized to vehicle control which
is set at 100% (n=3). ****: p<0.0001
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Primary Astrocytes are Responsive to IAA.
Consistent with our paradigm of analysis, we also sought to characterize if T-BSA has an
impact on IAA-induced cytotoxicity in primary astrocytes. First, in our concentration response
analysis for the effect of IAA in primary astrocytes, we found that primary astrocytes are
responsive to IAA after a 6-hour treatment, with the half maximal effective concentration (EC50)
required to elicit cytotoxicity as being approximately 40uM. This was the concentration used in
subsequent experiments.
T-BSA Does Not Enhance the Cytotoxic Effect of IAA in Primary Astrocytes.
Figure 22 shows that in primary astrocytes, treatment with 40uM IAA alone significantly
decreased cell viability (62.8% of control) compared to vehicle control after 6hrs (p<0.0001).
Co-treatment of T-BSA [0.1uM, 1uM, 10uM] with 40uM IAA did not significantly affect cell
viability compared to cells treated with 40uM IAA alone, and suggest that T-BSA is neither
directly cytotoxic to primary astrocytes, nor does it sensitize the cells to the effects of IAA.
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Figure 21. Concentration-Response for IAA-Induced Cytotoxicity in Primary Astrocytes.
Primary astrocytes were plated at 10,000 cells/well 24 hrs prior to treatment with IAA (6hr).
Primary astrocytes showed a concentration-dependent response to IAA where the half maximal
effective concentration (EC50) required to elicit cell death was 38.59uM. Cell viability was
assessed using a calceinAM assay (n=3).
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Figure 22. T-BSA Does Not Enhance the Cytotoxic Effect of IAA in Primary Astrocytes.
Primary astrocytes were plated at 10,000 cells/well 24 hrs prior to treatment. Cells were cotreated with IAA and T-BSA for 6hrs. Treatment with 40uM IAA alone significantly decreased
cell viability compared to vehicle control (10% CSFBS media) after 6hrs (p<0.0001). Cotreatment with T-BSA and 75uM IAA did not further reduce cell viability, relative to treatment
with IAA alone. Treatment with T-BSA alone, at either 0.1, 1 or 10 uM, did not have any
significant effect on cell viability. Co-treatment of 10uM BSA with 40uM IAA significantly
decreased cell viability compared to vehicle control (p<0.0001). 1mM IAA served as a positive
control for maximal cell death, while the 10uM BSA alone group served as the control for TBSA
application. Cell viability was assessed using a calceinAM assay. Data were normalized to
vehicle control which is set at 100% (n=3). ****: p<0.0001
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Summary of Results.
Through the experiments completed, we learned that:
1) T-BSA by itself is generally non-cytotoxic to either the glioma cells or primary astrocytes
2) The ability of T-BSA to sensitize (or augment) cytotoxicity associated with IAA or TMZ
is most noted in C6 glioma cells
3) T-BSA did augment the effect of TMZ in the chemotherapy-resistant T98G cells, but
timing of the treatment appeared to be a key factor.
4) T-BSA did not sensitize primary astrocytes to either IAA or TMZ
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CHAPTER FOUR
DISCUSSION
The data presented here demonstrate that each cell type utilized in this research exhibit
distinct responsiveness to not only the cytotoxic compounds IAA and TMZ, but also to the
putative membrane androgen receptor (membrane AR) ligand, T-BSA. Indeed, one major goal of
this research was to explore the how ligand binding to the putative membrane AR influences cell
viability/vulnerability in the presence of a cytotoxic insult. As previously mentioned, it has been
suggested that ligand binding to the membrane AR may induce damaging effects in certain cell
types, enhancing the effects of an introduced cytotoxic insult [20,21,22]. In the presence of two
distinct types of cellular insult, our lab has previously shown that binding to the membrane AR
through membrane-impermeable compounds is associated with a decrease in the phosphorylation
of the pro-survival signaling endpoints, ERK1/2 and Akt, as well as reduced expression of the
DNA repair enzyme, MGMT. Based on these observations, we anticipated that suppressing
inherent cell protection programs (e.g., reducing the activity of pro-survival pathways, or
reducing DNA repair capacity) would render cells more vulnerable. As such, we explored
whether this mechanism could be exploited in treating certain cancers. We focused on models of
glioma since our earlier work was done in cellular models of astrocytomas. Accordingly, we
evaluated the effect of T-BSA in C6 glioma cells, two models of glioblastoma (A172 and T98G
cells), and primary astrocytes. The latter was important as we wanted to know if T-BSA could
promote cell death, or vulnerability to a toxic insult, only in tumor models and not “normal”
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astrocytes. If so, there would be a particularly valuable utility to developing this approach further
as it would target the tumor cells while leaving normal, healthy cells unscathed.
In addition to evaluating the effects of T-BSA in different cell models, this project also explored
whether the “damage-promoting” effect of ligand binding to the membrane AR is dependent on
the mechanism of cytotoxicity. Therefore, we hypothesized that if the primary mechanism of the
membrane AR is to reduce those defenses that mitigate metabolic dysfunction and/or oxidative
stress, it is likely that T-BSA will have a significant effect in IAA-induced cytotoxicity;
alternatively, if the major mechanism of T-BSA (in a given cell type) is to reduce DNA repair
capacity (as previously discovered in C6 cells), then there may be more robust consequences to
T-BSA treatment when applied in the presence of TMZ, an alkylating agent that leads to DNA
damage.
Using C6 cells, the current data shows that T-BSA exacerbates cell vulnerability to
cytotoxic insult induced by both IAA (Fig. 2) and TMZ (Fig. 4). C6 cells co-treated with 10uM
T-BSA and 10uM IAA for 6 hours showed a 43.7% decrease in cell viability as compared to
cells treated with 10uM IAA alone over the same amount of time (Fig. 2). C6 cells co-treated
with 10uM T-BSA and 900uM TMZ for 48 hours showed a 22% decrease in cell viability as
compared to cells treated with 900uM TMZ alone over the same time course. Based on the data
utilizing C6 cells, it appears that the mechanism by which the membrane AR “promotes” cell
vulnerability may broadly impact cell survival pathways, weakening cell viability signaling to
render the cell vulnerable to either cytotoxic insult. However, the data also suggests that the
membrane AR’s capacity to induce these death-promoting effects may be dependent on cell type.
Although both A172 and T98G cells show concentration-dependent responsiveness to both IAA
and TMZ, the current data suggests that the presumed simultaneous presence of T-BSA with
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either IAA or TMZ does not enhance cell sensitivity to either cytotoxic insult in A172 (Fig. 7,
Fig. 14) or T98G (Fig. 8, Fig. 16) cells. Despite C6 cells being well-accepted as a model for
glioma [48, 49], limitations to using a cell model derived from chemically-induced tumors from
a non-human species remain. In particular, one literature review discussing chemically-induced
tumor cell lines notes that cell lines passaged over long periods of time may undergo genetic drift
in vitro, potentially resulting in overt sensitivity to certain experimental treatment and
subsequent overestimation of treatment efficacy [50]. Alternatively, the A172 cell line was
established from glioblastoma of a 53-year-old man, and the T98G cell line is derived from the
T98 cell line obtained from glioblastoma of a 61-year-old man [51]. Given that the type of tumor
a cell line is derived from may influence cell phenotype and genotype, thus contributing to cell
sensitivity to experimental treatments, this could be one explanation as to why treatment of TBSA with IAA or TMZ appears to have greater efficacy in C6 cells compared to A172 and T98G
cells. Despite the difference, one inference that we argue is important is that the C6 cells express
some cellular/molecular “feature” that renders the cell more responsive to the effects of T-BSA.
Based on this, it would be interesting to further explore the identity of this mediator of T-BSA.
The challenge here is compounded by the fact that the membrane AR is yet uncloned. However,
preliminary data from the Singh lab suggests that progesterone receptor membrane component-1
(Pgrmc1) might be a component of the membrane AR. Accordingly, and as one possible
hypothesis for future consideration, is that Pgrmc1 levels differ between the cell types, and
higher Pgrmc1 levels predict not only T-BSA binding to the cell surface of cells, but also the
extent to which T-BSA can promote the cytotoxicity of metabolic/oxidative insults.
The second aim of this research was to determine if presumed ligand binding to the
membrane AR sensitized A172 and T98G cells to treatment with TMZ. While treatment with
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TMZ is considered standard treatment for glioblastoma, the regimen often involves prolonged
systemic exposure and harsh side-effects, which can have negative impacts on patient quality of
life. Improvements to current TMZ treatment should aim to reduce systemic toxicity to, in turn,
reduce side effects, and improve patient quality of life. As previously discussed, ligand binding
to the membrane AR using T-BSA did not enhance cell sensitivity to cytotoxic insult under
conditions of co-treatment of T-BSA with TMZ. As an alternative approach to simultaneous
introduction of T-BSA and TMZ, we wanted to determine if pre-treatment with T-BSA prior to
treatment with TMZ would differentially influence cell viability, as compared to co-treatment.
The rationale for this approach was to consider that reduction in the levels of MGMT, the DNA
repair enzyme previously noted to be decreased in response to T-BSA, might take some time. As
such, the system would “benefit” from pre-treatment so as to reduce DNA repair defenses prior
to the administration of the chemotherapeutic. Alternatively, given that the membrane AR
remains uncloned and thus, not fully characterized, the presumed binding dynamics of T-BSA to
the membrane AR remain undefined as well. Accordingly, it is possible that the optimal binding
of T-BSA to the membrane AR occur over time such that effects of T-BSA might not be
observable through co-application of T-BSA and the “insult”. To explore this pre-treatment
model, A172 and T98G cells received an initial treatment with T-BSA for 24 hours before the
existing media was spiked with various concentrations of TMZ. While our paradigm of treatment
in the co-application experiments (i.e., when T-BSA and TMZ were administered concomitantly)
was to treat for 48 hours with TMZ, we also wanted to look at the response to a shorter duration
of treatment with TMZ (i.e., 24 hr) in the pre-treatment paradigm where T-BSA was applied 24
hr prior to TMZ. In A172 cells, TMZ did not effectively induce cell death after 24 hours,
supporting our assertion that 48 hours is the more ideal timeframe to evaluate the cytotoxic
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effects of TMZ. Additionally, pre-treatment with T-BSA for 24 hours prior to spiking media with
various concentrations of TMZ for an additional 24 hours did not induce any significant
decreases in cell viability (Fig. 9). We interpret that under conditions where no obvious signs of
cell dysfunction are noted (e.g., some, even modest, level of cell death), T-BSA in and of itself
does not have death-promoting effects. This is consistent with that noted in many of the figures
presented.
What was somewhat unexpected is that, in A172 cells, treatment with T-BSA for 24
hours prior to spiking media with various concentrations of TMZ for an additional 48 hours also
did not enhance the cytotoxic effects of TMZ (Fig. 10). We did, however, identify what we
conclude as a “statistical anomaly” in Figure 10, where A172 cells pre-treated with 1uM of TBSA for 24 hours prior to treatment with 200uM TMZ for an additional 48 hours showed a
paradoxical increase in cell viability compared to that noted with cells treated with 200uM TMZ
alone. However, there was not a statistical difference between cells treated with 200uM TMZ
alone and the vehicle control, which means that there was no effect of the presumptive toxin
(TMZ). As such, we don’t place much weight on the statistically significant difference between
the 1uM T-BSA+200 uM TMZ and the 200 uM TMZ alone groups.
While the effect of TMZ on T98G cells was relatively smaller, relative to that seen in
A172 cells, a result that is expected and based on reports that T98G cells are generally TMZresistant, we did notice a small but significant effect of 500uM TMZ on cell viability after both
24 hours and 48 hours. Pre-treatment with T-BSA for 24 hours prior to spiking media with
various concentrations of TMZ for an additional 24 hours did show an enhanced reduction in cell
viability in T98G cells relative to TMZ alone (Fig. 11). However, this enhanced cell
vulnerability was no longer seen in cells pre-treated with T-BSA for 24 hours prior to spiking
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media with TMZ for an additional 48 hours (Fig. 12). These findings may suggest that in T98G
cells, there may be an optimal time window in which T-BSA is capable of effectively engaging
the membrane AR while in the presence of TMZ, rendering cells more sensitive to TMZ for a
certain amount of time. Nevertheless, the data are encouraging from the standpoint that at least
one time point revealed a positive, death-enhancing effect of T-BSA, in the chemotherapeuticresistant T98G cell line. With respect to the A172 cells, the lack of observable enhancement of
TMZ-induced cell death by T-BSA may reflect more on the experimental tool used, recognizing
the caveat of not having a complete understanding of the binding dynamics of T-BSA (or the
stability of T-BSA in solution) in the various cell types studied. Future studies in the Singh lab
are aimed at addressing this, including using a new membrane AR – targeting ligand currently
under development.
In an effort to assess if the mechanism of the membrane AR is dependent on the type of
cytotoxic insult in human glioblastoma cells, we also looked at whether treatment with T-BSA
enhanced the cytotoxic effect of IAA in A172 and T98G cells. While A172 cells were responsive
to IAA (Fig. 13), co-treatment with T-BSA and IAA did not significantly enhance the cytotoxic
effect of IAA, compared to cells treated with IAA alone (Fig. 14). It is possible in this case that
treatment with 75uM IAA resulted in a “floor effect” in A172 cells, even though we chose the
EC50 value determined from a concentration-response analysis (see Figure 13). In this scenario,
we could argue that cell death associated with ligand binding to the membrane AR cannot be
differentiated from the cytotoxic effect of IAA alone.
Due to variable response of T98G cells to IAA, we were not able to discern whether TBSA alters IAA-induced cytotoxicity. As such, we believe the differences we noted between the
IAA group and the IAA + T-BSA groups are also a “statistical anomaly”. That is, even though
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co-treatment with T-BSA and 75uM IAA showed significant increases in cell viability relative to
treatment with 75uM IAA alone, it is important to note that 75uM IAA alone did not effectively
induce cell death in these experiments (i.e., no statistical difference relative to vehicle control).
Interestingly, there is literature which suggests that introducing hypoxic conditions, which results
in an increase in oxidative stress (which also occurs in response to treatment with IAA), may
stimulate tumor cells to increase exosome release which is thought to be beneficial to tumor cell
survival and homeostasis [52, 53, 60]. Several studies have suggested that altered exosomal
activity in tumor cells may help these cells more effectively eliminate chemotherapeutic and/or
cytotoxic drugs, potentially contributing to treatment resistance and drug-resistant phenotypes
[61, 62]. Although the current research did not further explore the potential changes in exosome
release in response to treatment with IAA, this is one area of research that could be extended in
the future.
The final aim of this research was to determine if the suggested “death-promoting” effect
associated with binding to the membrane AR enhances cell death in “normal” astrocytes, or if
this phenomenon was specific to cancer cells. Ideally, primary astrocytes, a cell model not
derived from tumor cells, do not respond to ligand binding to the membrane AR in a damaging
manner; the benefit here being selective targeting of cancer cells, as most current chemotherapies
result in cell death in both the target cell (i.e., the cancer cell) as well as non-cancer cells. Based
on the current data, primary astrocytes were seen to be similarly responsive to treatment with
TMZ (Fig. 17) compared to human glioblastoma cell lines. In primary astrocytes, co-treatment
with 1uM T-BSA and 200uM TMZ led to a statistically significant decrease in cell viability
compared to cells treated with 200uM TMZ alone, although the effect was relatively modest
(13.3% difference) (Fig. 18). Again, we wanted to explore whether the effect of pre-treatment
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with T-BSA differentially impacted cell viability compared to co-treatment with T-BSA and
TMZ. Pre-treatment with T-BSA for 24 hours prior to treatment with TMZ at various
concentrations for either 24 or 48 hours did not lead to any significant changes in cell viability.
Similar to the results seen with A172 cells, treatment with TMZ alone did not effectively induce
cell death in primary astrocytes after 24 hours (Fig. 19), whereas treatment with TMZ alone for
48 hours did significantly reduce cell viability at a higher TMZ concentration, yet this effect was
not enhanced by pre-treatment with TMZ prior to spiking the existing media with TMZ (Fig. 20).
Although the current data does not fully support that ligand binding to the membrane AR
enhances tumor cell sensitivity to TMZ, it does support the idea that this phenomenon is not seen
in “normal”, non-cancer cells. Since our lab has previously found evidence that primary
astrocytes do express the membrane AR, this difference in responsiveness to ligand binding is
perhaps due lower expression of the membrane AR in primary astrocytes, compared to tumor
cells.
Again, to assess if the mechanism of the membrane AR is dependent on the type of
cytotoxic insult, we looked at the effect of co-treating primary astrocytes with T-BSA and IAA.
While primary astrocytes are responsive to IAA (Fig. 21), co-treatment with T-BSA and IAA did
not significantly enhance the cytotoxic effect of IAA as compared to cells treated with IAA
alone, further suggesting that presumed ligand binding to the membrane AR does not promote
cell death in primary astrocytes. However, these findings were contrary to what we expected; as
mentioned, our lab has previously found evidence that treatment with DHT-BSA, as a presumed
ligand to the membrane AR, does enhance the cytotoxic effects of IAA in primary astrocytes
[20]. Perhaps this difference in membrane AR effect can be attributed to the use of different
presumed ligands (DHT-BSA versus T-BSA). This difference may be important when
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considering using the membrane AR as a therapeutic tool; in the case of using IAA as a cytotoxic
insult, it may be beneficial to use T-BSA rather than DHT-BSA in order to avoid inflicting
enhanced vulnerability in non-tumor primary astrocytes.
Overall, the current research aimed to further explore and understand the mechanisms by
which ligand binding to the putative membrane AR may influence cell vulnerability in response
to cytotoxic insults in different glioma cell models. The data here suggests that the “deathpromoting” effect of the membrane AR vary across cell types as a result of differential cellular
phenotypes and genotypes. This difference in effectively enhancing cell vulnerability can be
beneficial when considering the lack of effect seen in “normal” primary astrocytes.
Mechanistically, we view one logical future direction as one that determines whether a
correlation exists between the effectiveness of T-BSA as a cell death sensitizing/promoting agent
and the binding of T-BSA to the cell surface. It is possible that cell types, such as C6 cells have
higher levels of (surface) expression of the membrane AR (as assessed by flow cytometry, or
quantitative immunocytochemistry), allowing these cells to be more readily influenced by the
presence of a presumed ligand. However, assessing differences in membrane AR expression
remains a difficult at the present time since the membrane AR is yet uncloned, even though it has
been characterized pharmacologically [20,21].
When considering the exploitation of the membrane AR as a therapeutic tool to improve
the efficacy of chemotherapeutics, it is beneficial that non-cancer cells (i.e. primary astrocytes)
are not responsive to T-BSA in a way that would render cells more vulnerable to TMZ. Looking
at cell models for human glioblastoma, the data does not present strong findings to suggest that
ligand binding to the membrane AR significantly improves the efficacy of the chemotherapeutic
TMZ. One potential way to expand this research and better understand how engaging the
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membrane AR may influence cell viability would be to include additional time points at which
cell viability is assessed, in order to determine if there is a distinct time window in which
treatment with T-BSA and TMZ is the most optimal. As seen in the T98G cells, it appears that
there is a timepoint of about 24 hours in which T-BSA effectively influences cell viability. It is
possible that the effective timepoint for T-BSA in A172 falls outside of the 24- or 48-hour mark,
which could explain why there was no significant effects seen in the current data.
There are also clear limitations of using T-BSA (or its related analog, DHT-BSA) as the
sole experimental tool to evaluate the functional consequence of binding to the putative
membrane AR. First, it is a large and bulky compound (due, in particular, to the BSA moiety)
and would likely pose significant challenges as a clinically-used therapeutic. Our lab is currently
addressing potentially novel membrane AR ligands that may be more readily translatable. We
also recognize that it is not clear whether T-BSA is an agonist or antagonist (or inverse agonist),
and as such, we consistently define T-BSA as a “ligand” to the membrane AR.
Though we recognize that there remain questions surrounding the biology of the
membrane androgen receptor in various glial cell models, the current research does contribute
significantly to our current knowledge surrounding the membrane AR. Most notably, the data
generated as part of this Thesis project supports the conclusion that engaging the membrane AR
in C6 cells enhances the cytotoxic effects of both IAA and TMZ, rendering cells more sensitive
to distinct types of insult. This research also suggests that various glioma cell models are
differentially responsive to presumed ligand binding to the membrane AR, possibly attributed to
relative differences in the abundance of functional membrane AR. Future studies to better define
optimal conditions/methods for engaging the membrane AR may serve as a step forward in
improving chemotherapeutic treatment with TMZ by increasing cell vulnerability, specifically in
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cancer cells. Lastly, the current research supports the idea that the mechanism by which the
membrane AR promotes damaging effects can be used to intentionally target tumor cells, as
primary astrocytes were not shown to be negatively impacted by presumed engagement of the
membrane AR. This was a significant finding, in contrast to the experiments conducted with the
tumor models. This current research therefore provides further information that should be
expanded upon with the aim of improving current therapeutic tools used in the chemotherapeutic
treatment of glioblastoma, a disease for which the prognosis is exceedingly poor.
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